RPRX Royalty Pharma plc
$58.40▼ -1.11%
Healthcare
Other
Volume 709.8K
Avg Volume (10D) 3.77M
Key Metrics & Fundamentals
Market Cap
$33.74B
P/E Ratio
31.4
Div Yield
1.59%
52W Range
34.63 - 64.38
% vs 50 MA
-1.42%
% vs 200 MA
17.39%
RSI-14
44.1
MACD Histogram
-0.5300
Beta (1Y vs SPY)
0.27
Free Cash Flow
$728.46M
Gross Rev
$674.14M
Gross Profit
$674.14M
EBITDA
$142.12M
COGS
–
Operating Exp
$541.02M
Operating Income
$133.12M
EBIT
$133.12M
Pretax Income
$81.49M
Net Income
$17.88M
EPS (Diluted)
0.02
Price & Volume History
Loading chart…
Recent News
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
Insider Monkey · Sep 10, 2026 6:20 PM
Royalty Pharma to present at upcoming investor conferences
GlobeNewswire · Sep 9, 2026 8:05 PM
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Zacks · Sep 9, 2026 7:54 PM
Royalty Pharma Shares Fall After Novartis' Pelacarsen Fails Trial
MT Newswires · Sep 8, 2026 8:04 PM
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Benzinga · Sep 8, 2026 12:01 PM
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
GlobeNewswire · Sep 4, 2026 11:05 PM
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough
Insider Monkey · Sep 1, 2026 5:54 PM
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
Stocktwits · Aug 25, 2026 6:24 PM
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
Insider Monkey · Aug 13, 2026 10:27 PM
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Zacks · Aug 13, 2026 1:35 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See RPRX's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.